Optiver Holding
TVTX icon

Optiver Holding’s Travere Therapeutics TVTX Stock Holding History

Optiver Holding’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.55K Buy
254
+131
+107% +$3.92K ﹤0.01% 1295
2025
Q4 		$4.7K Sell
123
-435
-78% -$14.1K ﹤0.01% 1412
2025
Q3 		$13.3K Buy
558
+8
+1% +$150 ﹤0.01% 1126
2025
Q2 		$8.14K Buy
550
+146
+36% +$2.42K ﹤0.01% 1058
2025
Q1 		$7.24K Buy
+404
New +$8.2K ﹤0.01% 993

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Optiver Holding's TVTX Position: Q1 2026 in Review

Optiver Holding increased its Travere Therapeutics (TVTX) stake by 107% in Q1 2026, buying an estimated $3.92K and bringing the position to 254 shares worth $7.55K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

Optiver Holding first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $13.3K in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Optiver Holding held 254 shares of Travere Therapeutics worth $7.55K as of Q1 2026.
  • Optiver Holding bought 131 Travere Therapeutics shares in Q1 2026, an estimated $3.92K.
  • Travere Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1295 holding.
  • Optiver Holding first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Optiver Holding's Travere Therapeutics position peaked at $13.3K in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.